Skip to main content
Clinical Trials/NCT04846348
NCT04846348
Terminated
Phase 2

An Open-Label Pilot Study to Evaluate the Effectiveness and Tolerability of a Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis

Joseph Butterfield1 site in 1 country1 target enrollmentJuly 26, 2021

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Cutaneous Mastocytoses
Sponsor
Joseph Butterfield
Enrollment
1
Locations
1
Primary Endpoint
Cutaneous Symptom Relief
Status
Terminated
Last Updated
2 years ago

Overview

Brief Summary

The purpose of this study is to determine the effectiveness and tolerability of a novel topical preparation for the treatment of cutaneous lesions of mastocytosis.

Registry
clinicaltrials.gov
Start Date
July 26, 2021
End Date
September 10, 2021
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Joseph Butterfield
Responsible Party
Sponsor Investigator
Principal Investigator

Joseph Butterfield

Principal Investigator

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Cutaneous Symptom Relief

Time Frame: 2 weeks

Number of participants who achieve complete resolution or near-complete clearing of cutaneous symptoms of treated, involved skin

SkinDex-16 Quality of Life Questionnaire

Time Frame: 2 weeks

This validated questionnaire is a 16-item, participant-reported survey used to assess quality of life impacts due to the participant's skin condition. Scores range from 0 to 6, where 0 is never bothered by the skin condition and 6 is always bothered by the skin condition. Results are summed to produce an overall score, ranging from 0 to 96, where lower scores indicated a higher level of quality of life.

Study Sites (1)

Loading locations...

Similar Trials